Dostarlimab vs Toripalimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Dostarlimab

Marketed by GlaxoSmithKline and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT04655976 · Phase 2/3 · active, not recruiting

Patients were randomly assigned to three arms (758 enrolled) with docetaxel as the active comparator, but the study was open label, with no masking. The primary endpoint, overall survival, was not significantly improved by dostarlimab plus docetaxel (HR 0.96, 95% CI 0.77 to 1.20, p=0.37) or by the triplet with cobolimab (HR 0.85, 95% CI 0.68 to 1.06, p=0.08), so the primary comparisons were not met.

Next expected readout: January 2027 · NCT06879717 (registry estimate)

Reported efficacy

Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks); Overall Survival (OS) (Arm B Versus Arm C) (Up to approximately 234 weeks): Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) (missed)

Result source: NCT04655976

Toripalimab

Marketed by Coherus BioSciences, Inc. and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03856411 · Phase 3 · completed

This randomized, quadruple-blind, placebo-controlled trial of 465 patients met its primary endpoint: median progression-free survival was 8.4 months with toripalimab plus chemotherapy versus 5.6 months with placebo plus chemotherapy, a highly statistically significant improvement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT06426511 (registry estimate)

Reported efficacy

MPR rate in stage III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage III population evaluated by investigators (up to 3 years); MPR rate in stage II-III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage II-III population evaluated by investigators (up to 3 years): Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met. (met)

Result source: NCT04158440

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDostarlimabToripalimab
PFS, median4.4 vs 4.1vs Docetaxeln 305NCT04655976
2 other results
8.4 vs 5.6a+2.8 vs placeboNCT03856411
OS, median11.9 vs 11.3vs Docetaxeln 305NCT04655976
3 other results
—Not posted · NCT03856411
ORR18.7% vs 14.5%vs Docetaxeln 305NCT04655976
2 other results
—Not posted · NCT03856411
Duration of response, median8.3 vs 8.8vs Docetaxeln 57NCT04655976
2 other results
—Not posted · NCT03856411

PFS, median

Dostarlimab
4.4 vs 4.1vs Docetaxeln 305NCT04655976
2 other results
Toripalimab
8.4 vs 5.6a+2.8 vs placeboNCT03856411

OS, median

Dostarlimab
11.9 vs 11.3vs Docetaxeln 305NCT04655976
3 other results
Toripalimab
—Not posted · NCT03856411

ORR

Dostarlimab
18.7% vs 14.5%vs Docetaxeln 305NCT04655976
2 other results
Toripalimab
—Not posted · NCT03856411

Duration of response, median

Dostarlimab
8.3 vs 8.8vs Docetaxeln 57NCT04655976
2 other results
Toripalimab
—Not posted · NCT03856411
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dostarlimab: 3 of 4 rows · Toripalimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDostarlimabToripalimab
Dropout rate
25.6%Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
21.6%Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
—Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—
Discontinued due to AEs
—Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
—Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
—Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—
Serious AEs
33.8%Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
42.7%Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
58.3%Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—
Most frequent reported AEs
a
anaemia 34.8%
neutropenia 31.5%
fatigue 29.5%
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 2 more results
anaemia 31.5%
fatigue 29.8%
diarrhoea 29.5%
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
nausea 58.3%
diarrhoea 50%
fatigue 41.7%
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dostarlimab

Overall Survival 11.9 vs 11.3 Docetaxel months
time to event · months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
11.8 vs 11.3 Docetaxel months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
Overall Survival 11.9 months
time to event · months
No placebo or comparator arm
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
11.8 months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
ORR 18.7% (n=305) vs 14.5% (n=152) Docetaxel
responder rate · % of participants
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
18.3% (n=301) vs 14.5% (n=152) Docetaxel
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
Duration of Response 8.3 vs 8.8 Docetaxel months
time to event · months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
7.1 vs 8.8 Docetaxel months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
ORR 9.1% (n=11)
responder rate · % of participants
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 21.5 months
time to event · months
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
Disease Control 54.5% (n=11)
responder rate · % of participants
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
PFS 4.4 months
time to event · months
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Toripalimab's landscape